"Neuregulins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of peptides originally found as factors that stimulate the phosphorylation of the erbB-2 receptor (RECEPTORS, ERBB-2). Multiple variant forms of NEUREGULINS occur due to alternative splicing of their mRNAs. The NEUREGULINS include products from the three known genes (NGR1; NGR2 and NGR3).
Descriptor ID |
D020880
|
MeSH Number(s) |
D12.644.276.860.550 D12.776.467.860.550 D12.776.631.600.550 D23.529.850.550
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuregulins".
Below are MeSH descriptors whose meaning is more specific than "Neuregulins".
This graph shows the total number of publications written about "Neuregulins" by people in this website by year, and whether "Neuregulins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1997 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2002 | 1 | 0 | 1 |
2003 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuregulins" by people in Profiles.
-
Bexarotene normalizes chemotherapy-induced myelin decompaction and reverses cognitive and sensorimotor deficits in mice. Acta Neuropathol Commun. 2020 11 12; 8(1):193.
-
Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics J. 2018 07; 18(4):528-538.
-
Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 2003 Oct 31; 302(5646):826-30.
-
Integrins as developmental switches. Nat Cell Biol. 2002 Nov; 4(11):E253-5.
-
Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene. 1999 Jan 14; 18(2):305-14.
-
Neu differentiation factor (NDF), a dominant oncogene, causes apoptosis in vitro and in vivo. J Exp Med. 1998 Oct 19; 188(8):1535-9.
-
Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res. 1997 Sep; 3(9):1629-34.
-
Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene. 1996 Jun 20; 12(12):2535-47.